NeOnc Technologies HoldingsNTHI -0.90%7 EBIT per Share is $-1.71 as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 99.4% on this metric.
NeOnc Technologies Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.34.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.71.
During the past 3 years, the average EBIT per Share Growth Rate was -170.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NeOnc Technologies Holdings's EBIT per Share or its related term are showing as below:
NTHI'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -170.8 Med: -100.2 Max: -29.6
Current: -170.8
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of NeOnc Technologies Holdings was -29.60% per year. The lowest was -170.80% per year. And the median was -100.20% per year.
NTHI's 3-Year EBIT Growth Rate is ranked worse than 99.4% of 1173
companies
in the Biotechnology industry
Industry Median: 15.4
vs NTHI: -170.80
NeOnc Technologies Holdings (NAS:NTHI) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NeOnc Technologies Holdings EBIT per Share Related Terms
NeOnc Technologies Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeOnc Technologies Holdings (NTHI) has a EBIT per Share of $-1.71 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NeOnc Technologies Holdings and its competitors. According to the industry distribution chart, NeOnc Technologies Holdings ranks #1166 out of 1173 companies in the Biotechnology industry, placing it in the top 99.4%.
Is NeOnc Technologies Holdings' EBIT per Share too high?
NeOnc Technologies Holdings' current EBIT per Share is $-1.71. Based on the distribution chart, NeOnc Technologies Holdings ranks #1166 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' EBIT per Share compare to GUTS and PEPG?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #1166 out of 1173 companies for EBIT per Share. This places NeOnc Technologies Holdings in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NeOnc Technologies Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeOnc Technologies Holdings's current EBIT per Share is $-1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current EBIT per Share of $-1.71. The current EBIT per Share is $-1.71. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current EBIT per Share is $-1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score
Get the complete analysis for NTHI
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTHI has been successfully added to your 
